Modern topical treatment of psoriasis in diabetic patients
- Authors: Lykova S.G1, Nemchaninova O.B1, Svechnikova E.V.1, Morzhanayeva M.A1
-
Affiliations:
- Novosibirsk State Medical University
- Issue: Vol 27, No 4 (2020)
- Pages: 102-107
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312563
- DOI: https://doi.org/10.18565/pharmateca.2020.4.102-107
- ID: 312563
Cite item
Abstract
Full Text
About the authors
S. G Lykova
Novosibirsk State Medical UniversityDepartment of Dermatovenereology and Cosmetology
O. B Nemchaninova
Novosibirsk State Medical UniversityDepartment of Dermatovenereology and Cosmetology
Elena V. Svechnikova
Novosibirsk State Medical University
Email: elene-elene@bk.ru
Dr. Sci. (Med.), Associate Professor, Professor at the Department of Dermatovenerology and Cosmetology
M. A Morzhanayeva
Novosibirsk State Medical UniversityDepartment of Dermatovenereology and Cosmetology
References
- Данилов С.И., Нечаева О.С., Пирятинская А.Б. Медико-социальные факторы риска обострений хронических дерматозов. Российский журнал кожно-венерологических болезней. 2006;1:60-6.
- Walter J.F., Stoughton R.B., DeQuoy PR. Suppression of epidermal proliferation by ultraviolet light, coal tar and anthralin. Br J. Dermatol. 1978;99:89-96. Doi: 10.1111/ j.1365-2133.1978.tb01965.x.
- Gerritsen M.J., Rulo H.F., Van Vlijmen-Willems I., et al. Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D3: a cell biologic study. Br J. Dermatol. 1993;128:666-73. doi: 10.1111/j.1365-2133.1993.tb00263.x.
- Reichtrath J., Perez A., Muller S.M., et al. Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: an immunohistological evaluation. Acta Derm Venereol. (Stockh).1997;77:268-72. doi: 10.2340/00015555 772 682 72
- Lebwohl M., Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001;45:487-502. Doi: 10.1067/ mjd.2001.117046
- Duvic M., Nagpal S., Asano A.T., Chandraratna R.A. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol. 1997;37:18-24
- Weinstein G.D., Krueger G.G., Lowe N.J., et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol. 1997;37:85-92. Doi: 10.1016/ s0190-9622(97)70216-0.
- Hengge U.R., Ruzicka T., Schwartz R.A., Cork M.J. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1-15. doi: 10.1016/j.jaad.2005.01.010
- Dahl M.G.C. Hazards of topical steroid therapy. Adv Drug React Bull. 1985;115:428-31.
- Ammar N.M., Rao B., Schwartz R.A., Janniger C.K. Adolescent striae. Cutis. 2000;65:69-70.
- Lebwohl M.G., Tan M.H., Meador S.L., Singer G. Limited application of fluticasone propionate ointment 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol. 2001;44:77-82. Doi: 10.1067/ mjd.2001.110046.
- Ramsay B., Lawrence C.M., Bruce J.M., Shuster S. The effects of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol. 1990;23:73-6. doi: 10.1016/0190-9622(90)70189-o.
- Runne U., Kunze J. Short duration ("minutes") therapy with dithranol for psoriasis: a new outpatient regimen. Br J Dermatol. 1982;106:135-39. doi: 10.1111/j.1365-2133.1982.tb00922.x.
- Gelmetti C. Therapeutic moisturizers as adjuvant therapy for psoriasis patients. Am J Clin Dermatol. 2009;10:7-12. doi: 10.2165/0128071-200910001-00002.
- Witman P.M. Topical therapies for localized psoriasis. Mayo Clin Proc. 2001;76:943-49. doi: 10.4065/76.9.943.
- Bruner C.R., Feldman S.R., Ventrapragada M., Fleischer A.B. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol On-line J. 2003;9:2.
- Lebwohl M.G., Breneman D.L., Goffe B.S. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J. Am Acad Dermatol. 1998;39:590-96.Doi: 10.1016/ s0190-9622(98)70008-8.
- lebwohl M., Lombardi K., Tan M.H. Duration of improvement of psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0,05% ointment: comparison of maintenance treatments. Int J. Dermatol. 2001;40:64-6. doi: 10.1046/j.1365-4362.2001.01067-7.x.
- Kaidbey K., Kopper S.C., Sefton J., Gibson J.R. A pilot study to determine the effect of tazarotene 0.1% gel on steroid-induced epidermal atrophy. Int J. Dermatol. 2001;40:468-71. doi: 10.1046/j.1365-4362.2001.01234.x.
- Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J. Dermatol. 1999;38:16-24. doi: 10.1046/j.1365-4362.1999.00500.x.
- Дмитрук В.С. Опыт применения мази Карталин при ладонно-подошвенной форме псориаза идругих кератодермиях. Бюллетень сибирской медицины. 2011;1:112-16
- Солятова В.М. Оптимизация терапии псориаза с учетом изменений липидной плен ки в окологодовом ритме. Дисс. канд. мед. наук. Новосибирск, 2009